Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Blincyto"

The FDA ( Food and Drug Administration ) has granted approval of Blincyto ( Blinatumomab ) for the treatment of patients with Philadelphia chromosome-negative ( Ph- ) relapsed or refractory B-cell pre ...

Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto ) in adults with relapsed or refractory Philadelphia chromosome-positive ( ...